May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Psychometric Qualities of the National Eye Institute Visual Function Questionnaire-25 in Age-Related Macular Degeneration Patients in Two Clinical Trials
Author Affiliations & Notes
  • A. M. Rentz
    The Center for Health Outcomes Research, United BioSource Corporation, Bethesda, Maryland
  • D. A. Revicki
    The Center for Health Outcomes Research, United BioSource Corporation, Bethesda, Maryland
  • V. S. Thomas
    Health Economics & Outcomes Research, Novartis Pharma, Basel, Switzerland
  • Footnotes
    Commercial Relationships A.M. Rentz, Novartis, F; D.A. Revicki, Novartis, F; V.S. Thomas, Novartis, E.
  • Footnotes
    Support Novartis
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2096. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. M. Rentz, D. A. Revicki, V. S. Thomas; Psychometric Qualities of the National Eye Institute Visual Function Questionnaire-25 in Age-Related Macular Degeneration Patients in Two Clinical Trials. Invest. Ophthalmol. Vis. Sci. 2007;48(13):2096. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate the psychometric qualities of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in two ranibizumab clinical trials - ANCHOR and MARINA - in patients with age-related macular degeneration (AMD).

Methods:: The NEI VFQ-25 was administered to 1,146 patients with subfoveal choroidal neovascularization due to AMD with minimally classic or occult with no classic types in MARINA and predominantly classic type in ANCHOR at baseline and months 1, 2, 3, 6, 9 and 12. The SF-36 Health Survey was administered at baseline, and months 6 and 12. Visual acuity and other clinical assessments were completed throughout the studies. Internal consistency reliability, construct validity, and responsiveness were examined.

Results:: For the combined sample, average age was 77 (range 52-96) with 59% women. Internal consistency reliability was 0.96 for the VFQ-25 total score and ranged from 0.62 (ocular pain) to 0.91 (near activities) for the subscales. At baseline, the VFQ-25 total and subscale scores were significantly correlated with SF-36 subscale and summary scores (p<0.05). Total score, and near activities, distance activities and dependency subscale scores were significantly correlated with best corrected visual acuity (BCVA) and contrast sensitivity, and all scores varied by different BCVA groups (p<0.001). The VFQ-25 total, near activities, distance activities and dependency scores were most responsive to changes in BCVA over 12 months (all p<0.001). Visual acuity responders reported significantly better VFQ-25 scores compared to non-responders (p<0.001).

Conclusions:: The VFQ-25 total and subscales scores, especially near activities, distance activities, and dependency, are reliable and valid in patients with AMD. Based on these findings, the VFQ-25 represents a good measure of patient-reported vision-related quality of life outcomes for clinical trials comparing treatments for AMD.

Keywords: quality of life • retinal neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×